Status:
TERMINATED
Study of Dasatinib in Patients With Advanced Solid Tumors
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of Segment 1 of the study is to determine the effect of ketoconazole on dasatinib. The purpose of Segment 2 is to learn how dasatinib affects tumor growth in patients with advanced solid t...
Eligibility Criteria
Inclusion
- ECOG status 0-2
- Advanced or metastatic disease, unresponsive to standard treatment (or no standard treatment exists)
- Biopsy pretreatment
- Adequate bone marrow, liver and kidney function
Exclusion
- Serious cardiovascular disease
- Bleeding disorders
- Gastrointestinal (GI) tract disease
- Platelet inhibitors
- H2 blockers, proton pump inhibitors
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00162214
Start Date
August 1 2005
End Date
March 1 2007
Last Update
April 14 2011
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Lee S. Rosen M.D.
Santa Monica, California, United States, 90404
2
H. Lee Moffitt Cancer Center
Tampa, Florida, United States, 33612
3
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
4
Md Anderson Cancer Center
Houston, Texas, United States, 77030